Good news for Africans with river blindness


Victims of onchocerciasis could soon breathe a sigh of relief as a clinical trial begins in three African countries of a drug that could eliminate the disease. The trial takes place in Ghana, Liberia and DR Congo, Research and Training in Tropical Diseases and Wyeth announced via a teleconference at the WHO office in Accra, Ghana.
The Research Manager, Dr Annette Kuesel, said the new drug – Moxidectin – has the potential to kill or sterilize the adult worms of Onchocerca volvulus, which cause onchocerciasis or river blindness. Kuesel said the drug has been submitted to the Foods and Drugs Board (FDB) of Ghana for approval as well as for the smooth take off of the medical trial in the West African country.

“This is a devastating illness that has plagued 30 African countries for centuries, in particular the populations in the most remote areas ‘beyond the end of the road’,” said Dr Uche Amazigo, Director of the African Programme for Onchocerciasis Control (APOC) in a statement from WHO. “Over 100 million people are at risk of infection with onchocerciasis in Africa and a few small areas in the Americas and Yemen.”

Onchocerciasis is also called river blindness because the blackfly which transmits the disease breeds in fast flowing rivers, and blindness is the most incapacitating symptom of the disease which also causes debilitating skin disease.

The development of moxidectin for onchocerciasis is being conducted through a collaboration of the Special Programme for Research and Training in Tropical Diseases, which is executed by the World Health Organization (WHO/TDR), and Wyeth Pharmaceuticals. The work ranges from the development of a formulation for human use and initial studies in healthy volunteers, to clinical studies and community studies in Africa. WHO/TDR, working in partnership with African investigators and institutions, is building the capacity and managing the conduct of the clinical trials conducted in Africa. If the development is successful and results in a positive scientific opinion from the European Medicines Evaluation Agency, Wyeth, with the assistance of WHO, will request approval by national regulatory authorities in the countries where onchocerciasis is endemic.

Access

Dr Henrietta Ukwu, Vice President, Wyeth Pharmaceuticals, said, “Wyeth is committed to improving access to innovative drugs and biologics around the globe including in the developing world. The moxidectin data have been promising so far, and as the programme moves into larger phase III studies, we are hopeful that moxidectin will constitute a significant advance against this devastating disease.”

In conducting this trial, TDR will be working with African investigators and institutions. Fifteen hundred people at 4 sites in Ghana, Liberia and the Democratic Republic of Congo will be enrolled in the study. Preparation has been ongoing since 2007, and included building a clinical research centre in Lofa County, Liberia, and in Nord-Kivu in the Democratic Republic of Congo (DRC). Buildings not used since the war in Ituri, DRC, have been renovated. All centers have been provided with necessary equipment and the research teams trained on how to conduct the trial according to international standards.

Dr Robert Ridley, TDR’s director, added: “We work with national authorities and country partners to build research capacity and infrastructure. The training we provide to researchers and health care professionals and the experience they gather during the TDR sponsored studies enables them to conduct other clinical research later on, strengthening the health research systems in those countries.”

The trial will take place over the next two and a half years. Currently, the disease is controlled by ivermectin, which is donated by the pharmaceutical company Merck to the onchocerciasis endemic countries. Ivermectin kills the O. volvulus larvae but not the adult worms, so annual treatments for an extended period of time (at least 11-14 years) are required to ensure disease control. If moxidectin kills not only the larvae but also sterilizes or kills the adult worms, it has the potential to interrupt the disease transmission cycle within around 6 annual rounds of treatment. The drug could be distributed through the community-directed mechanisms set up in collaboration among APOC, African control programmes, and NGOs for the distribution of ivermectin.

About these ads

0 Responses to “Good news for Africans with river blindness”



  1. Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s




My tweets

Error: Twitter did not respond. Please wait a few minutes and refresh this page.

RSS AfricaNews

  • An error has occurred; the feed is probably down. Try again later.

RSS Ghana News

  • An error has occurred; the feed is probably down. Try again later.
July 2009
M T W T F S S
« Jun   Aug »
 12345
6789101112
13141516171819
20212223242526
2728293031  

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 70 other followers


Follow

Get every new post delivered to your Inbox.

Join 70 other followers

%d bloggers like this: